Qanatpharma Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
2
Qanatpharma General Information
Description
Operator of a biotechnology company intended to personalize microvascular medicine and reduce the socio-economic burden of cardiovascular disease. The company's microvascular pipeline focuses on understanding and treating microvascular dysfunctions, particularly in resistance arteries, through research into molecular patterns and signaling mechanisms, enabling hospitals, clinics, and medical professionals to improve patient outcomes.
Contact Information
Website
www.qanatpharma.comCorporate Office
- Residenzstrasse 18
- 80333 Munich
- Germany
Corporate Office
- Residenzstrasse 18
- 80333 Munich
- Germany
Qanatpharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Accelerator/Incubator | 01-Jan-2025 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC | 01-Jul-2023 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A) | 01-Jan-2020 | Completed | Startup | |||
| 1. Angel (individual) | 01-Jan-2018 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Qanatpharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Qanatpharma Patents
Qanatpharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019336540-A1 | Use of casein kinase 1 inhibitors for treating vascular diseases | Active | 09-Sep-2018 | ||
| AU-2019336540-B2 | Use of casein kinase 1 inhibitors for treating vascular diseases | Active | 09-Sep-2018 | ||
| CA-3111848-A1 | Use of casein kinase 1 inhibitors for treating vascular diseases | Pending | 09-Sep-2018 | ||
| EP-3846818-A1 | Use of casein kinase 1 inhibitors for treating vascular diseases | Pending | 09-Sep-2018 | ||
| US-20220047598-A1 | Use of casein kinase 1 inhibitors for treating vascular diseases | Pending | 09-Sep-2018 | A61K31/519 |
Qanatpharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Qanatpharma Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| University of Toronto Entrepreneurship | Accelerator/Incubator | |||
| Ventura BioMed Investors | Venture Capital | Minority |
Qanatpharma FAQs
-
When was Qanatpharma founded?
Qanatpharma was founded in 2017.
-
Where is Qanatpharma headquartered?
Qanatpharma is headquartered in Munich, Germany.
-
What is the size of Qanatpharma?
Qanatpharma has 9 total employees.
-
What industry is Qanatpharma in?
Qanatpharma’s primary industry is Drug Discovery.
-
Is Qanatpharma a private or public company?
Qanatpharma is a Private company.
-
What is Qanatpharma’s current revenue?
The current revenue for Qanatpharma is .
-
Who are Qanatpharma’s investors?
University of Toronto Entrepreneurship and Ventura BioMed Investors have invested in Qanatpharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
